NASDAQ:CHRS

Coherus BioSciences Earning Date

USA |NASDAQ |USD

CHRS Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.26 $-0.40 $0.33
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $91.69M $87.64M $113.55M

Coherus Biosciences's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

CHRS Earnings Date & History Chart

CHRS Earnings & Revenue Forecast

CHRS Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $-0.29 $-0.57 $-0.10
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $-1.23 $-2.78 $-0.65
Dec 2022 6 $-0.47 $-1.39 $0.88

CHRS Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-0.27 $-0.13 $-0.15
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-1.20 $-2.84 $-2.77
Dec 2022 0 / 1 $-0.43 $0.01 $-0.18

CHRS Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 6 $94.90M $80.32M $106.09M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 7 $359.33M $334.00M $378.69M
Dec 2022 7 $397.20M $333.44M $473.12M

CHRS Earnings Date & Revenue History

CHRS Earnings History

|
Show More
Show More

CHRS Revenue History

|
Show More
Show More

Coherus Biosciences Next Earnings Date & Report

CHRS Next Earnings Date & Report Preview: Sep 2021 (FQ)

CHRS's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 6 analysts, the average EPS estimation for Coherus Biosciences's next quarterly earnings is $-0.26, with a low EPS estimation of $-0.49, and a high estimation of $-0.13.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $-0.25, the last 2 month trend is $-0.11, and the 3 month trend is $-0.13.

Based on 6 analysts, the average revenue estimation is $91.69M, with a low revenue estimation of $83.00M, and a high estimation of $101.93M.

Coherus Biosciences Previous Earnings Dates & Reports

CHRS Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Coherus Biosciences's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

CHRS's earnings per share (EPS) was $-0.40, missing the consensus analysts forecast of $-0.15 by -169.54%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 77.15%, and lower than the same period a year before (Jun 2020) by -157.14%.

Revenues were $87.64M, worse than the forecast of $88.18M by -0.61%, up by 5.55% from the previous quarter , and down by -35.40% from the same period last year.

The company reported a net income of $-29.90M.

Free cash flow for the quarter was $-603.00K , compared to $1.22M last quarter and $57.81M a year before.

CHRS ended the quarter with $417.94M in total debt, an increase of 2.36% compared to the previous quarter, and a decrease of -34.07% compared to the same quarter a year before.

CHRS Previous Earnings Date & Report Recap: Dec 2020 (FY)

Coherus Biosciences's previous annual earnings date was Feb 24, 2021 for its fiscal year ended Dec 31, 2020.

CHRS's earnings per share (EPS) was $1.63, missing the consensus analysts forecast of $1.72 by -5.23% , and higher than the previous year's EPS (Dec 2019) by 36.97%.

Revenues were $475.82M, worse than the forecast of $480.61M by -1.00%, and up by 33.63% from previous year's revenue.

The company reported a net income of $132.24M, 47.21% higher than the previous year.

Coherus Biosciences reported a free cash flow of $146.91M for its fiscal year, compared to $15.46M a year ago.

The company ended the fiscal year with $404.26M in total debt, an increase of 114.30% compared to the previous year.